Structure of LRRK2 in Parkinson's disease and model for microtubule interaction.

Structure of LRRK2 in Parkinson's disease and model for microtubule interaction.
复制标题

DOI:
10.1038/s41586-020-2673-2
复制
发表时间:
2020-12
期刊:
影响因子:
64.8
通讯作者:
Leschziner AE
Leschziner AE
中科院分区:
综合性期刊1区
文献类型:
--
作者:
Deniston CK;Salogiannis J;Mathea S;Snead DM;Lahiri I;Matyszewski M;Donosa O;Watanabe R;Böhning J;Shiau AK;Knapp S;Villa E;Reck-Peterson SL;Leschziner AE

文献摘要

参考文献

被引文献

相似文献

亮氨酸富重复激酶2 (LRRK2)是家族性帕金森病(PD)中最常见的突变基因,也与其特发性形式有关。LRRK2被认为在膜运输中起作用,并与微管共定位。尽管LRRK2对于理解和治疗PD具有重要意义,但关于它的结构信息有限。在这里,我们报告了LRRK2催化一半的3.5Å结构,以及微管相关LRRK2的原子模型,该模型使用14Å低温电子断层扫描原位结构建立。我们提出LRRK2激酶结构域的构象调节其微管相互作用,其封闭构象有利于微管上的寡聚化。我们发现LRRK2的催化一半足以在体外形成细丝,并阻断微管马达马达激酶-1和细胞质动力蛋白-1的运动。稳定开放构象的激酶抑制剂减轻了这种干扰,减少了细胞中LRRK2丝的形成,而那些稳定封闭构象的激酶抑制剂则没有。我们的研究结果表明,LRRK2可以作为基于微管的马达的障碍,并对治疗性LRRK2激酶抑制剂的设计具有指导意义。
Leucine Rich Repeat Kinase 2 (LRRK2) is the most commonly mutated gene in familial Parkinson’s disease (PD) and is also linked to its idiopathic form. LRRK2 is proposed to function in membrane trafficking and co-localizes with microtubules. Despite LRRK2’s fundamental importance for understanding and treating PD, there is limited structural information on it. Here we report the 3.5Å structure of the catalytic half of LRRK2, and an atomic model of microtubule-associated LRRK2 built using a reported 14Å cryo-electron tomography in situ structure. We propose that the conformation of LRRK2’s kinase domain regulates its microtubule interaction, with a closed conformation favoring oligomerization on microtubules. We show that the catalytic half of LRRK2 is sufficient for filament formation and blocks the motility of the microtubule-based motors kinesin-1 and cytoplasmic dynein-1 in vitro. Kinase inhibitors that stabilize an open conformation relieve this interference and reduce LRRK2 filament formation in cells, while those that stabilize a closed conformation do not. Our findings suggest that LRRK2 can act as a roadblock for microtubule-based motors and have implications for the design of therapeutic LRRK2 kinase inhibitors.
DOI: 10.1016/j.bbrc.2009.08.163
发表时间: 2009-11-20
影响因子: 3.1
作者:
Greggio, Elisa;Taymans, Jean-Marc;Zhen, Eugene Yuejun;Ryder, John;Vancraenenbroeck, Renee;Beilina, Alexandra;Sun, Peng;Deng, Junpeng;Jaffe, Howard;Baekelandt, Veerle;Merchant, Kalpana;Cookson, Mark R.
通讯作者: Cookson, Mark R.
DOI: 10.1021/jm5018779
发表时间: 2015-05-14
影响因子: 7.3
作者:
Gilsbach, Bernd K.;Messias, Ana C.;Kortholt, Arjan
通讯作者: Kortholt, Arjan
DOI: 10.1107/s0907444904019158
发表时间: 2004-12-01
影响因子: 2.2
作者:
Emsley, P;Cowtan, K
通讯作者: Cowtan, K
DOI: 10.1016/s0092-8674(00)80360-8
发表时间: 1997-09-05
期刊: CELL
影响因子: 64.5
作者:
Case, RB;Pierce, DW;Vale, RD
通讯作者: Vale, RD
DOI: 10.1042/bcj20180803
发表时间: 2019-01-15
影响因子: 4.1
作者:
Deyaert, Egon;Leemans, Margaux;Versees, Wim
通讯作者: Versees, Wim